ResultsIQ

ResultsIQ › Latest results › Anthem Biosciences Limited

Anthem Biosciences Limited Q3 FY26 results deck summary

NSE: ANTHEM · BSE: 544449

Results deck of 5 Feb 2026, summarised by AI from the filing.

Q3FY26 revenue declined 15.0% YoY to ₹4,232 cr, but 9MFY26 EBITDA grew 22.6% to ₹6,712 cr with margin at 41.5%.

Key takeaways

  1. Q3FY26 revenue Revenue from operations was ₹4,232 cr, down 15.0% year-on-year and 23.1% quarter-on-quarter.
  2. 9MFY26 EBITDA EBITDA grew 22.6% to ₹6,712 cr with margin at 41.5%.
  3. Exceptional item Labour Codes led to an exceptional item of ₹254 cr, impacting PBT and PAT.
  4. Demand Underlying demand remains robust, with the historically strongest quarter still ahead.
  5. Margin Margin improvement neutralised the revenue shortfall in the quarter.

Original filing on BSE

Anthem Biosciences Limited Q1 FY27 results

As filed: Revenue ₹418 cr (−23% year on year), EBITDA ₹151 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 36.0% (+63 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹583 cr, EBITDA ₹267 cr, PAT ₹212 cr, EBITDA margin 45.8%. Not scored. No result for the same quarter last year. Share price after the results: +1.4% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹417 cr, EBITDA ₹163 cr, PAT ₹112 cr, EBITDA margin 39.1%. Not scored. No result for the same quarter last year. Share price after the results: +21.1% in 30 days (Nifty 500: +2.8%).
  • Q2 FY26: Revenue ₹552 cr, EBITDA ₹225 cr, PAT ₹198 cr, EBITDA margin 40.8%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹538 cr, EBITDA ₹196 cr, PAT ₹148 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year. Share price after the results: +10.4% in 30 days (Nifty 500: +2.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

Anthem Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.